Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. We are committed to delivering innovative treatments to improve the quality of life for patients with CNS disorders. Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union and Switzerland (both 2015) as well as in the U.S. (2017) and is commercialized in Europe by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the US. Valeo Pharma holds the commercialization rights for the Canadian market, Seqirus for Australia & New Zealand, and Medison for Israel. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indications. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, under the trading symbol NWRN, on the primary market of the Düsseldorf Stock Exchange and on XETRA, trading symbol NP5.